Biosimilar Biologics Do Not Always Reduce Out-of-Pocket Costs
By Lori Solomon HealthDay Reporter
TUESDAY, April 2, 2024 -- Biosimilar competition is not consistently associated with lower out-of-pocket (OOP) costs for commercially insured outpatients, according to a study published online March 29 in JAMA Health Forum.
Kimberly Feng, M.D., from Brigham and Women’s Hospital in Boston, and colleagues investigated whether biosimilar competition is associated with lower OOP spending for patients using biologics. The analysis included national claims data (Optum Clinformatics Data Mart) for 190,364 individuals (younger than 65 years of age) with outpatient claims for one of seven clinician-administered biologics (filgrastim, infliximab, pegfilgrastim, epoetin alfa, bevacizumab, rituximab, and trastuzumab) from January 2009 through March 2022.
The researchers found that annual OOP costs increased before and after biosimilar availability. Compared with the year before biosimilar competition, two years after the start of biosimilar competition, the adjusted odds ratio of nonzero annual OOP spending was 1.08 and average nonzero annual spending was 12 percent higher. Claims for biosimilars were more likely than reference biologics to have nonzero OOP costs (adjusted odds ratio, 1.13) but had lower mean nonzero OOP costs (adjusted mean ratio, 0.92). There was variance by drug.
"Findings of this study suggest that the introduction of biosimilar competition did not systematically lower patient OOP spending on biologics, highlighting the need for targeted policy interventions to ensure that savings from biosimilar competition improves affordability for patients," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.